Efficacy, Immunogenicity and Safety of an Investigational Subunit Adjuvanted Herpes Zoster Vaccine in Adults Aged 60 Years and Older: Results From the ZOE-50 and ZOE-70 Efficacy Studies
journal contribution
posted on 2024-07-26, 01:21authored byJanet E McElhaney, Himal Lal, Anthony L Cunningham, Myron J Levin, Roman Chlibek, Javier Diez-Domingo, Eugene AthanEugene Athan, Johan Berglund, H Jackson Downey, Wayne Ghesquière, Olivier Godeaux, Iris Gorfinkel, Shinn-Jang Hwang, Tiina Korhonen, Shelly McNeil, Karlis Pauksens, Joan Puig-Barberà, Thiago J Avelino-Silva, Timo Vesikari, Antonio Volpi, Daisuke Watanabe, Wilfred Yeo, Laura Campora, Carline Vanden Abeele, Lidia Oostvogels, Thomas C Heineman
Efficacy, Immunogenicity and Safety of an Investigational Subunit Adjuvanted Herpes Zoster Vaccine in Adults Aged 60 Years and Older: Results From the ZOE-50 and ZOE-70 Efficacy Studies